News
NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, reported financial results for the quarter ended June 30, 2025, and provided a corporate update. The Company highlighted ...
More than half of patients prescribed medical cannabis for chronic musculoskeletal pain stop using it within a year, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback